A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Work at Intra-Cellular Therapies Inc. has led to the identification of heterocycle fused gamma-carbolines characterized as 5-HT2A receptor ligands reported to be useful for the treatment of neurological disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized new benzimidazole derivatives acting as serine/threonine-protein kinase SIK inhibitors.
Gasherbrum Bio Inc. has described GLP-1 receptor agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others.
Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation.
Exelixis Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized oxoisoindolinyl substituted piperidinedione derivative molecular glue degraders characterized as IKZF1, IKZF3 and GSPT1 degradation inducers. They are reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
RSS